Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche ’s Hemlibra in people with moderate or mild haemophilia A

Basel, 13 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from an interim analysis of the phase III HAVEN 6 study, which show Hemlibra ® (emicizumab) demonstrated a favourable safety profile and effective bleed control in people with moderate or mild haemophilia A without factor VIII inhibitors.3 The data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition as an oral presentation on 12 December 2021.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news